FDA Grants Vascular BioSciences Humanitarian Use Device (HUD) Designation to the Endoarterial Biopsy Catheter for Group 1 Pulmonary Arterial Hypertension

Vascular Biosciences (VBS) is pleased to announce the receipt of a Humanitarian Use Device (HUD) designation from the U.S. Food and Drug Administration (FDA) for the Endoarterial Biopsy Catheter (EABC) to take pulmonary artery biopsies in patients who have Group 1 pulmonary arterial hypertension... - September 06, 2019 - Vascular BioSciences, Inc

Global Regenerative Group & Kanfit3D Enter Into Distribution Partnership

Global Regenerative Group & Kanfit3D Enter Into Distribution Partnership

Pleased to announce a new distribution partnership between Global Regenerative Group, a company which has developed extensive experience in the most advanced medical device industries, and Kanfit3D. - September 05, 2019 - Global Regenerative Group

Biosynthetic Technologies Inks Patent License Agreement with Cayman Chemical for the Global Pharmaceutical and R&D Markets

Biosynthetic Technologies (BT) today announced it has signed on with Cayman Chemical for the production and distribution of novel Estolide compounds for pharmaceutical testing applications. BT is excited to partner with Cayman Chemical to provide discovery and pre-clinical development services to... - September 05, 2019 - Cayman Chemical Company

Thrivous Earns Better Business Bureau Accreditation

Better Business Bureau (BBB) of Utah has accredited Thrivous. After review, BBB determined that Thrivous meets its Standards for Trust: build trust, advertise honestly, tell the truth, be transparent, honor promises, be responsive, safeguard privacy, and embody integrity. Thrivous has committed to... - September 04, 2019 - Thrivous

CrystalGenomics Receives Orphan Drug Designation from the US FDA for CG-745 in Pancreatic Cancer

CrystalGenomics, Inc. (KOSDAQ: 083790) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CG-745, a clinical stage histone deacetylase (HDAC) inhibitor being developed for several hematologic malignancies and solid tumors, for the treatment of... - August 30, 2019 - CrystalGenomics, Inc.

Dr. David Dayton Joins Thrivous Science Advisor Board

Dr. David Dayton has joined the science advisor board at Thrivous, the human enhancement company. The board informs ongoing product and service development, reflecting Thrivous' commitment to guidance from consensus science in its mission to help customers access technology with the greatest... - August 28, 2019 - Thrivous

Thrivous Upgrades Clarity with Bioavailable Vitamin B Complex

Thrivous, the human enhancement company, has upgraded Clarity, the daily nootropic, to include bioavailable Vitamin B Complex. Clarity is a cognitive enhancement supplement that Thrivous developed to improve focus, memory, and mood. Thrivous designed formula 2 of Clarity to support brain function... - August 21, 2019 - Thrivous

Zifo RnD Solutions and Scilligence Announce Strategic Partnership

Zifo RnD Solutions and Scilligence Corporation announce a strategic partnership that enables Zifo to provide System Integrations Solutions for Scilligence suite of integrated informatics solutions. The partnership will help clients to easily select, evaluate, and implement solutions that fit their... - August 18, 2019 - Zifo RnD Solutions

New Research Benchmarks Clinical Investigator Satisfaction with Pharma Sponsors and Central Laboratories

8-year Study Tracks Central Lab Performance and Identifies Covance as Leading the Way in Clinical Investigator Satisfaction. - August 13, 2019 - Life Science Strategy Group, LLC

Thrivous Launches Alpha, the Extended Daily Nootropic

Thrivous, the human enhancement company, has developed and brought to market Alpha, the extended daily nootropic. Alpha is designed for daily use to support long-term brain function. It is also designed to complement Clarity, Serenity, and Surge, nootropics previously developed and brought to... - August 11, 2019 - Thrivous

Arteric Named a Top 100 Healthcare Marketing Agency by MM&M

Arteric Named a Top 100 Healthcare Marketing Agency by MM&M

Latest accolade follows a year of 30% revenue growth and thought leadership. - August 09, 2019 - Arteric

Advances in Medicine Cause New, Groundbreaking Drug by Quantum Genomics (QNNTF) to Help with Chronic Hypertension

Quantum Genomics are the creators of Firibastat, a first-in-class brain aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the brain to interfere with the renin-angiotensin system. It is estimated that there are around 150 million people... - August 05, 2019 - Quantum Genomics

Global Regenerative Group Becomes Global Partner for Pharmaceutical Wholesaler Prosupplier GmbH Representing Their CureOs® Synthetic BONE GRAFT

Global Regenerative Group Becomes Global Partner for Pharmaceutical Wholesaler Prosupplier GmbH Representing Their CureOs® Synthetic BONE GRAFT

Global Regenerative Group, developer and global distributor of new and innovative products in the field of Regenerative Medicine, today announces its partnership with Prosupplier GmbH, a pharmaceutical wholesaler with an experienced and specialist team, whose products include CureOs® Synthetic BONE GRAFT. - August 02, 2019 - Global Regenerative Group

Thrivous Launches Surge, the Acute Nootropic

Thrivous, the human enhancement company, has developed and brought to market Surge, the acute nootropic. Surge is designed for occasional use to increase energy and focus, and to reduce side effects from caffeine. It is also designed to complement Clarity and Serenity, nootropics previously... - August 01, 2019 - Thrivous

Brewing a Cure 4 ALS Fundraiser Invites You to Enjoy Regional Beers and Wines While Fundraising for ALS Research

Brewing a Cure 4 ALS Fundraiser Invites You to Enjoy Regional Beers and Wines While Fundraising for ALS Research

On Saturday, August 10, 2019, the first-ever Brewing a Cure 4 ALS fundraiser will be held at Technology Square in Cambridge, MA. Brewing a Cure 4 ALS invites community members to enjoy craft beer, wine, music, and food with the goal of raising money for ALS research at the ALS Therapy Development... - July 31, 2019 - ALS Therapy Development Institute

On August 18, Wear Your Nerdiest Costume and Run for a Great Cause at the Race 4 Research 5K in Cambridge

On August 18, Wear Your Nerdiest Costume and Run for a Great Cause at the Race 4 Research 5K in Cambridge

On Sunday, August 18, the ALS Therapy Development Institute (ALS TDI) will host the annual Race 4 Research 5K and Walk in Technology Square, Cambridge. The event will feature a chip-timed nerdy 5K road race (costumes encouraged), a 4-mile ALS awareness walk and wheelchair ride along the Charles,... - July 26, 2019 - ALS Therapy Development Institute

Hans Kaspersetz Shares Arteric's Approaches to Leveraging Artificial Intelligence in Healthcare Marketing at Digital Pharma West

Hans Kaspersetz Shares Arteric's Approaches to Leveraging Artificial Intelligence in Healthcare Marketing at Digital Pharma West

Two Case Studies Illustrate the Impact of AI on Accelerating Business, and the Insights That Result - June 23, 2019 - Arteric

Multiplex ELISAs Offer Powerful Profiling Capabilities

Cayman now offers multiplex immunoassay technology powered by Quansys Biosciences. This line of fully quantitative Q-Plex™ multiplex ELISAs and chemiluminescent Q-View™ imagers provides a highly sensitive means to simultaneously measure multiple markers using a single sample. - June 22, 2019 - Cayman Chemical Company

BraveHeart Wireless Announces FDA Clearance of the BraveHeart™ Life Sensor Cardiac Monitoring System

BraveHeart Wireless Announces FDA Clearance of the BraveHeart™ Life Sensor Cardiac Monitoring System

The BraveHeart™ Life Sensor Cardiac Monitoring system has been cleared for use in health care settings. The Life Sensor monitoring system securely captures patients’ heart rate and EKG data, and transmits the data to health care providers in real time. More than 28 million Americans diagnosed with heart disease may benefit - with this number growing each year. - June 20, 2019 - BraveHeart Wireless Inc.

Orangetheory Fitness and Augie’s Quest Collaboration Funds Innovative Research at the ALS Therapy Development

Orangetheory Fitness and Augie’s Quest Collaboration Funds Innovative Research at the ALS Therapy Development

This past May over 1,100 members of Orangetheory Fitness ran, rowed, and lifted, earning “splat points,” which they turned into $4.5 million in donations for Augie’s Quest to Cure ALS. With this donation Augie’s Quest is supporting non-profit biotech, the ALS Therapy Development Institute (ALS TDI), to fast track cure-driven drugs for ALS. - June 20, 2019 - ALS Therapy Development Institute

AMT Partners with Medicare for Educational Webinar: Critical Medicare Documentation Requirements for Wound Care Residents

American Medical Technologies has partnered with Durable Medical Equipment Medicare Administrative Contractors (DME MACs), Noridian Healthcare Solutions and CGS Administrators, to host a live educational webinar covering Medicare’s documentation requirements for wound care residents. - June 18, 2019 - American Medical Technologies

The OMEGATOF, a Fully Integrated Benchtop Spectrometer Instrument for High-Mass MALDI Applications with the Power of CovalX Technology Inside

CovalX has partnered with Shimadzu Scientific Instruments to offer the OMEGATOF, an integrated MALDI solution for ultra high-mass detection. With a focus on the detection of large molecules, including biotherapeutics, protein complexes, aggregates, and antibody-antigen interactions in a benchtop... - June 13, 2019 - CovalX

New Research Benchmarks Pharma’s Changing Utilization of Real-World Evidence (RWE) and Its Impact on Contract Research Organizations (CROs)

Study Tracks Utilization of Real-World Data (RWD), Real-World Evidence (RWE) and Supportive Services and Implications to CROs. - June 11, 2019 - Life Science Strategy Group, LLC

Ingredient Alliance Announces Launch of Pharma Grade CBN/CBG/THCV and Early Harvest Biomass

Ingredient Alliance Announces Launch of Pharma Grade CBN/CBG/THCV and Early Harvest Biomass

Designer Cannabinoids take center stage at Ingredient Alliance. - June 11, 2019 - Ingredient Alliance

Global Regenerative Group (GRG) Announced That the Global Regenerative Academy Has Been Launched

Global Regenerative Group (GRG) Announced That the Global Regenerative Academy Has Been Launched

The Global Regenerative Academy is an integral part of the Global Regenerative Group, a privately-held medical technologies company specializing exclusively on Regenerative Medicine and stem cell technologies, products, and therapies that significantly enhance the body’s natural healing ability. - June 06, 2019 - Global Regenerative Group

Matreya, LLC is Now a Part of Cayman Chemical Company to Better Serve the Lipid Community

Cayman Chemical, an industry-leading supplier of bioactive lipids, analytical standards, and contract lipidomic services, announced today that it has acquired Matreya, LLC, a lipid biochemical company located in State College, Pennsylvania, with strengths in synthesis, extraction, and purification of natural products. Matreya stocks a wide selection of high-purity sphingolipids, phospholipids, fatty acids and esters, and sterols to be used as research standards. - June 05, 2019 - Cayman Chemical Company

BPOG Extractables Testing of AdvantaPure(R)’s Key Silicone and TPE Tubing Products is Complete; Test Results Help Drug Manufacturers Compare Tubing

BioPhorum Operations Group extractables testing was recently completed on several of AdvantaPure’s tubing and hose products. The fluid transfer products are typically used in biopharm and pharmaceutical manufacturing processes. The Group’s standardized extractables test protocol was followed and performed by an independent lab and involved testing to four different exposure times as long as 70 days. The comprehensive testing was undertaken by AdvantaPure to meet customer requests. - May 31, 2019 - AdvantaPure

Pillar Clinical Research Announces New Ratings Initiative: Pillar Precision

Pillar Clinical Research Announces New Ratings Initiative: Pillar Precision

The Dallas based research company plans to roll out a new clinical rating training program, Pillar Precision. The program includes a clinician guide featuring best practices for specific CNS indications, placebo response training, malingering detection, data-driven decision making, and multi-site... - May 24, 2019 - Pillar Clinical Research

Apostle Inc. Completes Series A Financing Led by ShangBay Capital

Apostle Inc. is pleased to announce the completion of its series A financing, raising $3.3 million. The investment round is led by ShangBay Capital, a Silicon Valley-based venture capital firm, focused on investing in early stage medical device and biotech companies. Three other Silicon... - May 24, 2019 - Apostle Inc

First Responders Unite to Arrest and Extinguish ALS

First Responders Unite to Arrest and Extinguish ALS

Inaugural Arrest and Extinguish event at Tanglewood raises over $50,000 for ALS research. - May 23, 2019 - ALS Therapy Development Institute

First Responders Unite to End ALS at Inaugural Arrest & Extinguish Event

On May 18th, first responders will unite for a tug-of-war event at Tanglewood to raise money for ALS research. - May 11, 2019 - ALS Therapy Development Institute

Arteric Advances Healthcare Marketing and Engagement Campaigns at Biopharma eMarketing Summit

Arteric Advances Healthcare Marketing and Engagement Campaigns at Biopharma eMarketing Summit

President and Chief Strategist Shares Two Case Studies That Illustrate How to Leverage Artificial Intelligence to Achieve Business Goals. - May 10, 2019 - Arteric

Eurofarma Synapsis Receives Registrations Until June 21

Sustainable entrepreneurship platform in Latin America in partnership with Endeavor, encourages innovation in health area. - May 09, 2019 - Eurofarma

Scientists at AbboMax Developed Antibodies Against PINK1 and Parkin to Study Parkinson’s Disease

A panel of PINK1 and Parkin antibodies was developed at Abbomax to investigate Parkinson’s disease (PD). These phosphospecific and paired antibodies would be useful tools for studies of PINK/Parkin pathways and signaling in PD. AbboMax has been developing & manufacturing high performance immunoassay reagents for many years in California. AbboMax specializes in high-quality custom service and products focusing on antibody and assay development. - May 09, 2019 - AbboMax, Inc.

Oxytocin Exposure During Labor Influences Offspring Development: Offspring Demonstrated Long-Term, Epigenetic Changes in Brain & Behavior After a Single Administration

A research team from the Kinsey Institute, Indiana University, the University of Virginia and Northeastern University recently discovered that a single exposure to oxytocin near the time of birth can have effects in the offspring, including increases in social behaviors that may persist into adulthood. - May 07, 2019 - Kinsey Institute

Reuters to Make Documentary on Paras Biopharmaceuticals Finland Oy – Innovations in Biologics: Insights of a Leading Expert

Reuters to Make Documentary on Paras Biopharmaceuticals Finland Oy – Innovations in Biologics: Insights of a Leading Expert

Paras Biopharmaceuticals Finland Oy is proud to announce that Reuters.com / Reuters Plus has selected the Finland-based company, working on biologics manufacturing & innovations in the healthcare segment as a valued contributor to the future of healthcare solutions. The documentary is part of... - May 07, 2019 - Paras Biopharmaceuticals Finland Oy

May is ALS Awareness Month - #AskMeAboutALS

May is ALS Awareness Month. The ALS Therapy Development Institute is inviting the general public to participate, and hoping to inspire a larger dialogue around ALS, through #AskMeAboutALS. - May 01, 2019 - ALS Therapy Development Institute

NanoCellect Biomedical Begins Distribution to Europe

NanoCellect Biomedical Inc., a leader in the development and manufacture of microfluidic cell sorting solutions for cell-based assays, today announced an exclusive distribution agreement with Basel, Switzerland-based Bucher Biotec AG. The agreement covers sales in Switzerland of NanoCellect’s... - May 01, 2019 - NanoCellect

MD Stem Cells New Alzheimer’s Treatment Shows Early Benefits

Initial memory improvements following ACIST stem cells may hold promise for ALZ. - April 24, 2019 - MD Stem Cells

Texas Clinical Research Company Announces Expansion and New Quality Assurance Initiative

Texas Clinical Research Company Announces Expansion and New Quality Assurance Initiative

Pillar Clinical Research (Pillar), with a focus on early and late stage CNS drug development, opens two new US research facilities in Illinois and Arkansas and adds Director of Quality Assurance. Dr. Andrew Kim joined the Chicago team in September of 2018, and has spent over 5 years in clinical... - April 18, 2019 - Pillar Clinical Research

Zifo RnD Solutions Announces Launch of Sci-Desk

Zifo RnD Solutions announced the launch of its latest product Sci-Desk, an on-demand, cloud-based, Scientific Application Support-in-a-box. Sci-Desk offers comprehensive managed services for Scientific & lab computing systems spanning Discovery, R&D and Manufacturing industries. “Sci-Desk is a first of its kind in the Life Science R&D Spectrum. Sci-Desk brings on-demand, scalable, customizable and secure support to scientific applications,” said Raj Prakash, CEO/Co-Founder of Zifo RnD Solutions. - April 18, 2019 - Zifo RnD Solutions

YouScript and Genome Medical Announce Partnership to Provide Clinical and Analytics Support for Genetic Risk Management

Connecting precision medicine analytics and genetic services - April 03, 2019 - YouScript

Standigm Raises US $11.5 Million in Series B Round Funding to Advance Its AI-Powered Drug Pipelines Toward License-Out

Standigm, an AI-powered drug discovery company, has raised $11.5 million in a Series B funding round. The funds will be used to scale the AI technology platforms and advance its drug discovery pipelines for untreatable diseases. - March 29, 2019 - Standigm

Are Antioxidants the Solution to Burning and Itchy Eyes?

A recently published study in The Ocular Surface journal authored by Experimentica Ltd. in collaboration with researchers from Loyola University Chicago and the University of Missouri – Kansas City suggests that a topical antioxidant formulation can improve the pathological signs associated with dry-eye disease. - March 26, 2019 - Experimentica Ltd

Huntington Study Group Achieves 100th Credentialed Research Site Milestone

Huntington Study Group Achieves 100th Credentialed Research Site Milestone

The Huntington Study Group (HSG), a world leader in spearheading research and conducting clinical trials in Huntington disease (HD), is excited to announce that it has credentialed Inland Northwest Research, LLC as the 100th HSG site in North America. “On behalf of myself and our site, I... - March 25, 2019 - Huntington Study Group

Daryn Henry Joins Arteric as Creative Director

Daryn Henry Joins Arteric as Creative Director

Veteran Digital Communicator Brings Decades of Award-Winning Experience to Boundary-Pushing Agency. - March 15, 2019 - Arteric

Arteric Explores Current Uses of Artificial Intelligence and Machine Learning to Accelerate Digital NPP Engagement for Biotechnology and OTC Brands

Arteric Explores Current Uses of Artificial Intelligence and Machine Learning to Accelerate Digital NPP Engagement for Biotechnology and OTC Brands

Arteric Shares Case Studies with Life Science Leaders, Illustrating Methods to Increase the Relevance and Authority of Brand Content. - March 14, 2019 - Arteric

New Low-Height, Low-Frequency Vibration Isolation Platform Adapts to Space Constraints in Critical Micro- and Nano-Microscopy

New Low-Height, Low-Frequency Vibration Isolation Platform Adapts to Space Constraints in Critical Micro- and Nano-Microscopy

At just 2-1/4 inches in height, while isolating vibrations as low as 1 hertz, the new completely-passive Negative-Stiffness tabletop vibration isolation platform – developed by Minus K Technology – provides the industry’s thinnest low-height, low-frequency isolator for optimizing space in critical microscopy and laboratory applications. - March 14, 2019 - Minus K Technology Inc.

BioTork and Lallemand Biofuels & Distilled Spirits Enter Joint Development Collaboration

BioTork and Lallemand Biofuels & Distilled Spirits Enter Joint Development Collaboration

BioTork, LLC and Lallemand Biofuels & Distilled Spirits (LBDS) a business unit of Lallemand Inc. are pleased to jointly announce the formalization of a collaboration for the development of improved yeast strains for the ethanol industry. “BioTork has been working with Lallemand, a world... - March 11, 2019 - BioTork

Scintica Instrumentation to Distribute the VelO2x Hypoxia Chamber System from Baker Ruskinn

Scintica Instrumentation Inc. is excited to announce its recent distribution agreement for the Baker Ruskinn preclinical VelO2x hypoxia chamber for scientific research. The VelO2x system has been engineered to provide an isolated and highly controlled oxygen environment to help researchers better understand how O2 levels affect various conditions such as sleep apnea, systemic hypertension, pulmonary dysfunction, ischemia and much more. - March 07, 2019 - Scintica Instrumentation

Press Releases 151 - 200 of 2,966